Author Archives for

AEON Biopharma Announces FDA Acceptance of IND for ABP-450 as a Treatment for Cervical Dystonia; Secures $25 Million Investment

-Critical milestone transitions AEON Biopharma to clinical-stage company--Moving directly into Phase 2 clinical trial expected to begin in the first half of 2021--Investment expected to provide funding for clinical programs…

AEON Biopharma Appoints BOTOX® Therapeutic Head as President and Chief Executive Officer

Dynamic Industry Veteran Led Multi-Billion Dollar Therapeutic Neurotoxin Portfolio NEWPORT BEACH, Calif., May 13, 2019 /PRNewswire/ -- ALPHAEON Corporation announced today that its Board of Directors has named Marc Forth as President and Chief Executive…